Champions Biotechnology, Inc. Appoints Three Key Executives to Management Team
Arlington, VA – January 20, 2009 – Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has appointed three key executives to the company’s management team. They are: Mark Schonau as Chief Financial Officer; Sara Parkerson, RN, MSN, OCN, CCM as Director of Personalized Oncology Services US; and Elizabeth Bruckheimer, PhD as Director of Preclinical Development. Durwood C. Settles, who had served as acting CFO, has been named the company’s Controller.
“The growth we are experiencing in all of our business segments has mandated these additions to our team. I am pleased to welcome Mark, Sara and Beth to Champions,” said Doug Burkett, PhD, President of Champions Biotechnology, Inc. “The breadth of their experience is a testament to the good work we are doing at Champions. Each of these individuals brings tremendous expertise to the leadership roles they will undertake.”
Mark Schonau brings more than twenty-five years of leadership in financial and operations management to Champions and will serve as Chief Financial Officer. Mr. Schonau previously served as Chief Financial Officer for Insys Therapeutics a development stage biopharmaceutical company focused on discovering, developing, and commercializing products to address cancer-related pain and CINV. Prior to that, Mr. Schonau served as CFO of Axway, Inc., a leading global provider of collaborative business solutions from January 2006 through August 2007. From January 2001 to January 2006, Mr. Schonau served as CFO and Senior Vice President of Administration for Cyclone Commerce, a business-to-business systems provider that was acquired by Axway in 2006. Upon Cyclone’s acquisition by Axway, Mr. Schonau became the North American Chief Financial Officer of the surviving entity. From 1988 to 2000, Mr. Schonau also served as CFO for two public companies; Viasoft (NASDQ – VIAS) and CyCare (NYSE – CYS). Mr. Schonau was also employed by the accounting firm of Ernst & Young LLP from January 1981 to May 1988. He is a member of the Arizona and American Institutes of Certified Public Accountants and currently sits on the board of directors of the Arizona Technology Council. Mr. Schonau received a Bachelors degree in Accounting from Arizona State University.
Sara Parkerson, RN, MSN, OCN, CCM, is an oncology nurse with not only a strong clinical background, but also a solid foundation in business, disease management operations, case management, and health care consulting. Ms. Parkerson is running daily operations for Champions’ Personalized Oncology services; a role in which she is working directly with patients and doctors.
Prior to joining Champions, Ms. Parkerson was Vice President of Oncology Services for Matria Healthcare. Ms. Parkerson was responsible for development of new clinical products and services for the oncology program, covering the full continuum of cancer care. Previously, she was in the role of Director of Oncology Case Management Operations starting in 2002. Prior to joining Matria, Ms. Parkerson worked in healthcare consulting with Cap Gemini Ernst & Young from 1997 to 2002, a role that included projects involving care management operations, design, and implementation of clinical information systems, process redesign, and cancer program evaluation. She has over 25 years of oncology nursing experience and holds a Masters degree in Nursing from Catholic University of America and a Bachelors degree in Nursing from American University. She is an Oncology Certified Nurse and a Certified Case Manager.
Elizabeth Bruckheimer, PhD, is a cancer biologist and pharmacologist with a strong scientific and managerial background in preclinical and translational science and cancer drug development in both academic and industry settings. Dr. Bruckheimer will manage the day-to-day operations of the Champions’ Preclinical Platform and Preclinical eValuation programs. She will also support the internal drug development programs and the Personalized Oncology programs at Champions.
Prior to joining Champions, Dr. Bruckheimer was Associate Director & Manager at Systems Medicine, LLC from 2007 to 2008 where she led preclinical and translational research programs. From 2003 to 2007, Dr. Bruckheimer was a Senior Scientist in cancer biology, at MedImmune, Inc., where she was involved in several preclinical and translational programs focused on monoclonal antibodies, cancer vaccines, and small molecule technologies for the treatmentof cancer. From 2001 to 2003, Dr. Bruckheimer was a Scientist II, at Targeted Genetics Corporation, involved in gene therapy programs aimed at treating cancer, cystic fibrosis, hemophilia, and AIDS. Dr. Bruckheimer holds a Bachelors degree in Biochemistry from the University of Arizona and a Doctorate in Biomedical Sciences from the University of Texas M.D. Anderson Cancer Center.